Skip to content

Risk Scoring Systems in Upper GI-haemorrhage

Risk Scoring Systems in Upper GI-haemorrhage

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01589250
Enrollment
831
Registered
2012-05-01
Start date
2009-08-31
Completion date
2012-04-30
Last updated
2012-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Gastrointestinal Hemorrhage

Brief summary

Use of risk scoring systems in the assessment of patients presenting with upper gastrointestinal haemorrhage is increasing. Comparative studies have intended to identify the system of choice, but the majority of these are characterized by retrospective designs, small sample sizes, low rate of severe bleeding, or low mortality. The main aim of this study was to identify the optimal scoring system.

Interventions

None listed

Sponsors

Odense University Hospital
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

One of the following: * Haematemesis * Melaena * Coffee-ground vomit

Design outcomes

Primary

MeasureTime frameDescription
Need for hospital-based intervention1 monthNeed of hospital-based intervention was defined as treatment with blood transfusion, endoscopic therapy, transcatheter arterial embolization (TAE), surgery, or identification of cancer at upper endoscopy.

Secondary

MeasureTime frameDescription
Identification of low-risk patients1 monthLow-risk patients were defined as patients who did not need hospital-based intervention, and survived more than 30 days from day of admission. Low-risk patients were considered as suitable for early discharge and potential outpatient management.
Rebleeding1 monthRebleeding was defined as presence of hematemesis, blood per nasogastric tube, or melaena associated with a decline in B-hemoglobin of at least 1mmol/l (not explained by hemodilution) or decline in systolic arterial pressure of at least 20mmHg after the initial bleeding had stopped.
30 day mortality30 days

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026